Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice
Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of mRNA encoding human FGF21 proteins. The efficac...
Salvato in:
Autori principali: | , , , , , , , , , , , , , , , |
---|---|
Natura: | Libro |
Pubblicazione: |
Elsevier,
2022-06-01T00:00:00Z.
|
Soggetti: | |
Accesso online: | Connect to this object online. |
Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
Collocazione: |
A1234.567 |
---|---|
Copia 1 | Disponibile |